Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

The Journal of clinical endocrinology and metabolism·2003

Same author

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.

Diabetologia·2003

Same author

Repaglinide at a cellular level.

Diabetes, nutrition & metabolism·2003

Same author

No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects.

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity·2003

Same author

Cocaine- and amphetamine-regulated transcript is present in hypothalamic neuroendocrine neurones and is released to the hypothalamic-pituitary portal circuit.

Journal of neuroendocrinology·2003

Same author

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.

Proceedings of the National Academy of Sciences of the United States of America·2003

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

GLP-1 in NIDDM

¹Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark.

Diabetic Medicine : a Journal of the British Diabetic Association

|September 1, 1996

Summary

Glucagon-like peptide-1 (GLP-1) is a hormone that lowers blood glucose by stimulating insulin and reducing glucagon. GLP-1 therapy normalizes hyperglycemia in NIDDM without hypoglycemia risk, with research focusing on oral administration.

Area of Science:

Endocrinology
Molecular Biology

Background:

Glucagon-like peptide-1 (GLP-1) is an insulinotropic hormone produced by intestinal expression of the glucagon gene.
GLP-1 receptors, which are G-protein coupled receptors activating adenylate cyclase, are present in pancreatic islets, brain, and other tissues.

Purpose of the Study:

To explore the therapeutic potential of GLP-1 in managing hyperglycemia, particularly in non-insulin-dependent diabetes mellitus (NIDDM).
To investigate the mechanisms by which GLP-1 affects glucose regulation and gastrointestinal function.

Main Methods:

Review of existing literature on GLP-1's physiological effects and therapeutic applications.
Analysis of GLP-1's impact on insulin secretion, glucagon inhibition, hepatic glucose production, and gastrointestinal activity.

More Related Videos

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Main Results:

GLP-1 administration normalizes hyperglycemia in NIDDM without causing hypoglycemia due to its glucose-dependent insulinotropic effects.
GLP-1 inhibits glucagon secretion, reducing hepatic glucose production and lowering blood glucose levels.
GLP-1 also inhibits gastrointestinal secretion and motility, potentially aiding in controlling postprandial glucose excursions.

Conclusions:

GLP-1 is a promising therapeutic agent for NIDDM due to its efficacy in normalizing blood glucose without hypoglycemia risk.
Challenges include the peptide nature of GLP-1 requiring parenteral administration and its low bioavailability due to rapid enzymatic degradation.
Ongoing research focuses on developing orally active GLP-1 analogues to improve therapeutic utility.